<DOC>
	<DOCNO>NCT00784966</DOCNO>
	<brief_summary>The purpose study determine prolonged administration anti TNF ( tumor necrosis factor ) -Alpha agent etanercept associate enhanced graft survival patient undergoing islet kidney transplantation .</brief_summary>
	<brief_title>Islet After Kidney Transplant Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients type 1 diabetes mellitus , stable function renal transplant , take appropriate maintenance immunosuppression severe health problem preclude receive islet transplant consider inclusion . Have history finding suggestive unstable diabetic complication ( e.g . active eye disease ) Active infection ( clinically laboratory test ) History current malignancy suspicion malignancy properly investigate exclude Liver biliary abnormality Unstable cardiovascular disease Findings suggest immunological sensitization woman potential get pregnant use sufficient method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Islet transplantation</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>